Ono Pharmaceutical expands multi-target research collaboration with Congruence Therapeutics
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
ValiRx establishes animal health subsidiary to target veterinary oncology market
FDA accepts rusfertide NDA and grants priority review for polycythemia vera
UAE approves PYRUKYND for treatment of thalassaemia
Sanofi's rilzabrutinib receives orphan drug designation in Japan for IgG4-related disease
Genflow Biosciences receives first EUR336,467 tranche of EUR4m Wallonia grant
Atrium Therapeutics launches as newly independent, publicly traded company
Innovent Biologics' Jaypirca approved in China for new indication
Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial
Neurizon Therapeutics doses first participant in NUZ-001 Regimen I HEALEY ALS Platform Trial
Melodia Therapeutics reports award of US patent covering MLD-151